Epstein Secrets

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. The office also said Collins may have broken House ethics rules by persuading National In

essed no disagreement with the panel's Democrat, Pennsylvania Rep. Susan Wild, who said she expected to move "rather quickly" on writing new rules. Taylor sees the tasks as "very narrow," focused on preventing lawmakers from serving in outside positions that could pose conflicts. The remarkable thing i

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. The office also said Collins may have broken House ethics rules by persuading National In

ssed no disagreement with the panel's Democrat, Pennsylvania Rep. Susan Wild, who said she expected to move "rather quickly" on writing new rules. Taylor sees the tasks as "very narrow," focused on preventing lawmakers from serving in outside positions that could pose conflicts. The remarkable thing i

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. EFTA00085695 The office also said Collins may have broken House ethics rules by persuad

ssed no disagreement with the panel's Democrat, Pennsylvania Rep. Susan Wild, who said she expected to move "rather quickly" on writing new rules. Taylor sees the tasks as "very narrow," focused on preventing lawmakers from serving in outside positions that could pose conflicts. The remarkable thing i

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. The office also said Collins may have broken House ethics rules by persuading National In

essed no disagreement with the panel's Democrat, Pennsylvania Rep. Susan Wild, who said she expected to move "rather quickly" on writing new rules. Taylor sees the tasks as "very narrow," focused on preventing lawmakers from serving in outside positions that could pose conflicts. The remarkable thing i

he Office of Congressional Ethics reported that it found "a substantial reason to believe" that Collins violated federal law by touting the stock of Innate Immunotherapeutics, an Australian biotech firm, based on inside information. The office also said Collins may have broken House ethics rules by persuading National In

ssed no disagreement with the panel's Democrat, Pennsylvania Rep. Susan Wild, who said she expected to move "rather quickly" on writing new rules. Taylor sees the tasks as "very narrow," focused on preventing lawmakers from serving in outside positions that could pose conflicts. The remarkable thing i